Clinical trial
Spiriva® Assessment of FEV1 (SAFE)
NCT00277264 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00277264 |
|---|---|
| Title | Spiriva® Assessment of FEV1 (SAFE) |
| Official title | Spiriva® Assessment of FEV1 (SAFE). The Effect of Inhaled Tiotropium Bromide (18 Mcg Once Daily) on the Change in FEV1 During Long-term Treatment in Patients With COPD. A One-year Parallel Group, Double-blind, Randomised, Placebo-controlled Study |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Drug |
| Interventions | Tiotropium (Spiriva®) |
| Enrollment | 914 |
| Start date | Jan 1, 2002 |
| Primary completion | May 1, 2004 |
| Completion | May 1, 2004 |
| First posted | Jan 16, 2006 |
| Last update posted | Nov 6, 2013 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: